OROS® Hydromorphone Prolonged Release
Authors:
- 1 April 2010
- journal article
- research article
- Published by Springer Nature in CNS Drugs
- Vol. 24 (4) , 337-361
Abstract
OROS® hydromorphone prolonged release (OROS® hydromorphone) [Jurnista™] is a once-daily formulation of the opioid agonist hydromorphone that utilizes OROS® (osmotic-controlled release oral delivery system) technology to deliver the drug at a near constant rate, thereby providing consistent analgesia over a 24-hour period. It is indicated for use in patients with severe pain and contra-indicated in those with acute or post-operative pain. In several, randomized, multicentre, phase III trials, oral OROS® hydromorphone administered once daily for up to 52 weeks was generally effective in the treatment of patients with chronic, moderate to severe cancer or non-malignant/noncancer pain with regard to improvements from baseline to end-point in patient-assessed measures of pain intensity, pain relief and/or functional impairment. Pharmacoeconomic analyses suggest that OROS® hydromorphone provides greater cost utility than other opioids in this patient population. In addition, OROS® hydromorphone was generally well tolerated in clinical trials, with most adverse events being mild to moderate in severity and similar to those seen with other opioids. Thus, OROS® hydromorphone is an effective and useful alternative to other opioids for the treatment of patients with severe pain.Keywords
This publication has 53 references indexed in Scilit:
- An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS® hydromorphone in patients with chronic cancer painBMC Palliative Care, 2009
- A randomized, double-blind comparison of OROS®hydromorphone and controlled-release morphine for the control of chronic cancer painBMC Palliative Care, 2008
- Once-daily OROS® hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration studyInternational Journal Of Clinical Practice, 2007
- Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphoneCurrent Medical Research and Opinion, 2007
- Fatal Respiratory Depression after??Multiple Intravenous Morphine InjectionsClinical Pharmacokinetics, 2006
- HydromorphoneJournal of Pain and Symptom Management, 2005
- Hydromorphone-3-glucuronideLife Sciences, 2001
- Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration: Treatment strategiesJournal of Pain and Symptom Management, 1997
- The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complexLife Sciences, 1994
- Pharmacokinetics and Bioavailability of Hydromorphone Following Intravenous and Oral Administration to Human SubjectsThe Journal of Clinical Pharmacology, 1981